Extended Antitumor Responseof a BRAF V600E Papillary Thyroid Carcinoma to Vemurafenib

Extended Antitumor Responseof a BRAF V600E Papillary Thyroid Carcinoma to Vemurafenib

Context: For patients with metastatic papillary thyroid carcinoma (PTC) refractory to radioactive iodine (RAI) treatment, systemic chemotherapy has limited efficacy. Such tumors frequently harbor BRAF V600E, and this alteration may predict responsiveness to vemura-fenib treatment. Objective: We repo...

Full description

Bibliographic Details
Main Authors: Siraj M. Ali, Je He, Wade Carson, Phil J. Stephens, Joseph Fiorillo, Doron Lipson, Gary A. Palmer, Jeffrey S. Ross, Vincent A. Miller, Jeffrey Sharman
Format: Article
Language:English
Published: Karger Publishers 2014-05-01
Series:Case Reports in Oncology
Subjects:
BRAF V600E
Vemurafenib
Papillary thyroid carcinoma
Online Access:http://www.karger.com/Article/FullText/363377

Internet

http://www.karger.com/Article/FullText/363377

Similar Items